FAS Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13M Buy
10,858
+443
+4% +$453K 0.68% 35
2026
Q1
$9.58M Buy
10,415
+350
+3% +$355K 0.6% 44
2025
Q4
$10.8M Buy
10,065
+291
+3% +$278K 0.7% 34
2025
Q3
$7.46M Buy
9,774
+235
+2% +$175K 0.51% 44
2025
Q2
$7.44M Buy
9,539
+574
+6% +$446K 0.55% 41
2025
Q1
$7.4M Buy
8,965
+109
+1% +$90.7K 0.6% 40
2024
Q4
$6.84M Buy
8,856
+3,218
+57% +$2.66M 0.57% 41
2024
Q3
$4.99M Buy
5,638
+109
+2% +$98K 0.4% 57
2024
Q2
$5.01M Buy
5,529
+93
+2% +$74.4K 0.43% 54
2024
Q1
$4.23M Sell
5,436
-75
-1% -$53.4K 0.37% 61
2023
Q4
$3.21M Buy
5,511
+103
+2% +$60.1K 0.31% 74
2023
Q3
$2.9M Buy
5,408
+140
+3% +$72.1K 0.31% 73
2023
Q2
$2.47M Sell
5,268
-623
-11% -$261K 0.31% 74
2023
Q1
$2.02M Buy
5,891
+3
+0.1% +$1.01K 0.22% 96
2022
Q4
$2.15M Sell
5,888
-7
-0.1% -$2.48K 0.24% 90
2022
Q3
$1.91M Buy
5,895
+950
+19% +$301K 0.21% 84
2022
Q2
$1.6M Sell
4,945
-85
-2% -$25.5K 0.17% 92
2022
Q1
$1.44M Buy
5,030
+4
+0.1% +$1.03K 0.14% 101
2021
Q4
$1.39M Sell
5,026
-16
-0.3% -$4.06K 0.13% 104
2021
Q3
$1.17M Sell
5,042
-86
-2% -$21.2K 0.11% 117
2021
Q2
$1.18M Buy
5,128
+4
+0.1% +$803 0.11% 117
2021
Q1
$957K Buy
5,124
+805
+19% +$157K 0.1% 127
2020
Q4
$729K Sell
4,319
-10
-0.2% -$1.49K 0.08% 140
2020
Q3
$641K Sell
4,329
-225
-5% -$34.8K 0.09% 142
2020
Q2
$748K Sell
4,554
-194
-4% -$29.8K 0.11% 124
2020
Q1
$659K Buy
4,748
+4
+0.1% +$550 0.12% 117
2019
Q4
$624K Buy
4,744
+111
+2% +$12.9K 0.11% 125
2019
Q3
$518K Buy
4,633
+3
+0.1% +$334 0.09% 129
2019
Q2
$513K Buy
4,630
+3
+0.1% +$353 0.1% 129
2019
Q1
$600K Sell
4,627
-144
-3% -$17.5K 0.12% 115
2018
Q4
$552K Sell
4,771
-202
-4% -$22.6K 0.13% 116
2018
Q3
$534K Buy
4,973
+2
+0% +$200 0.12% 110
2018
Q2
$424K Buy
4,971
+4
+0.1% +$329 0.11% 124
2018
Q1
$384K Sell
4,967
-201
-4% -$16.2K 0.11% 128
2017
Q4
$436K Sell
5,168
-322
-6% -$27.4K 0.11% 119
2017
Q3
$470K Sell
5,490
-597
-10% -$49K 0.13% 112
2017
Q2
$501K Buy
6,087
+3
+0% +$245 0.15% 92
2017
Q1
$512K Buy
6,084
+103
+2% +$8.25K 0.16% 92
2016
Q4
$440K Buy
5,981
+4
+0.1% +$298 0.13% 98
2016
Q3
$480K Buy
5,977
+3
+0.1% +$240 0.16% 84
2016
Q2
$470K Sell
5,974
-997
-14% -$75.1K 0.17% 81
2016
Q1
$502K Sell
6,971
-1,447
-17% -$109K 0.26% 49
2015
Q4
$709K Buy
8,418
+3
+0% +$249 0.35% 40
2015
Q3
$704K Sell
8,415
-97
-1% -$8.19K 0.41% 32
2015
Q2
$711K Buy
8,512
+152
+2% +$11.6K 0.36% 33
2015
Q1
$607K Buy
8,360
+2
+0% +$142 0.31% 34
2014
Q4
$577K Sell
8,358
-778
-9% -$52.5K 0.3% 34
2014
Q3
$592K Sell
9,136
-18
-0.2% -$1.14K 0.34% 27
2014
Q2
$569K Sell
9,154
-515
-5% -$30.7K 0.33% 28
2014
Q1
$569K Sell
9,669
-498
-5% -$27.8K 0.39% 23
2013
Q4
$519K Buy
+10,167
New +$509K 0.31% 26

Other funds holding LLY

FAS Wealth Partners's LLY Position: Q2 2026 in Review

FAS Wealth Partners increased its Eli Lilly (LLY) stake by 4.3% in Q2 2026, buying an estimated $453K and bringing the position to 10,858 shares worth $13M. The position accounts for 0.68% of the portfolio, ranked #35.

FAS Wealth Partners first reported a position in LLY in Q4 2013 and has held it in 51 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • FAS Wealth Partners held 10,858 shares of Eli Lilly worth $13M as of Q2 2026.
  • FAS Wealth Partners bought 443 Eli Lilly shares in Q2 2026, an estimated $453K.
  • Eli Lilly made up 0.68% of FAS Wealth Partners's portfolio in Q2 2026, its #35 holding.
  • FAS Wealth Partners first reported a position in Eli Lilly in Q4 2013 and has held it in 51 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.